[{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"}]